Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | See Remarks | July 01, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date July 01, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 34,705 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 34,705 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $294.61 · Expires 2033-02-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This option vested in three equal annual installments beginning March 1, 2024. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $336.48 · Expires 2034-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: This option vests in three equal annual installments beginning March 1, 2025. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $305.86 · Expires 2035-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: This option vests in three equal annual installments beginning March 1, 2026. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $287.55 · Expires 2036-02-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: This option vests in three equal annual installments beginning March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in three equal annual installments beginning March 1, 2024.
F2: This option vests in three equal annual installments beginning March 1, 2025.
F3: This option vests in three equal annual installments beginning March 1, 2026.
F4: This option vests in three equal annual installments beginning March 1, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 25,339 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 4,562 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 12,402 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 12,271 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)
F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
F3: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
F4: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
F5: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.
F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2023 Filed Feb 28, 2023 23:02 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002997 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,015 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2020-2022 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:13 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,257 | $0.00 Strike: $294.61 | $0.00 |
DisclosureSEC source: 0001225208-23-002830 · doc4.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,257 Underlying: Common Stock, $.01 Par Value · 6,257 shares Expires 2033-02-22 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2024. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:13 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002830 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,945 F1 · shares: These restricted stock units vest in three equal annual installments beginning March 1, 2024. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,490 | $0.00 Strike: $197.35 | $0.00 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · derivative · entry 10 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,490 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. F3 · derivative.exercise_date: This option was granted on February 28, 2018. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,012 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · derivative · entry 9 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,012 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. F2 · derivative.exercise_date: This option was granted on February 27, 2019. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,012 | $183.44 | $369,082.29 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 6 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,490 | $197.35 | $491,401.50 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 5 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,781 | $0.00 Strike: $197.35 | $0.00 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · derivative · entry 8 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock, $.01 Par Value · 9,781 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. F3 · derivative.exercise_date: This option was granted on February 28, 2018. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,886 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · derivative · entry 7 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,012 Underlying: Common Stock, $.01 Par Value · 6,886 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. F2 · derivative.exercise_date: This option was granted on February 27, 2019. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 9,781 | $333.09 | $3,257,953.29 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,750 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 6,886 | $335.00 | $2,306,810.00 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,531 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 6,886 | $183.44 | $1,263,171.28 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:01 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 9,781 | $197.35 | $1,930,280.35 |
DisclosureSEC source: 0001225208-22-012577 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2022. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 23:15 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,897 | $0.00 Strike: $149.14 | $0.00 |
DisclosureSEC source: 0001225208-22-008760 · doc4.xml · derivative · entry 5 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,897 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. F2 · derivative.exercise_date: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 23:15 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,897 | $149.14 | $432,044.10 |
DisclosureSEC source: 0001225208-22-008760 · doc4.xml · nonDerivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 23:15 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,505 | $0.00 Strike: $149.14 | $0.00 |
DisclosureSEC source: 0001225208-22-008760 · doc4.xml · derivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 Underlying: Common Stock, $.01 Par Value · 9,505 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. F2 · derivative.exercise_date: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 23:15 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 9,505 | $280.00 | $2,661,400.00 |
DisclosureSEC source: 0001225208-22-008760 · doc4.xml · nonDerivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,853 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 23:15 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 9,505 | $149.14 | $1,417,528.18 |
DisclosureSEC source: 0001225208-22-008760 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 21:29 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,104 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-22-008322 · doc4.xml · derivative · entry 5 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,104 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. F2 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 21:29 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 1,104 | $139.22 | $153,698.88 |
DisclosureSEC source: 0001225208-22-008322 · doc4.xml · nonDerivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:29 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,458 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-22-008322 · doc4.xml · derivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104 Underlying: Common Stock, $.01 Par Value · 3,458 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. F2 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:29 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 3,458 | $270.00 | $933,660.00 |
DisclosureSEC source: 0001225208-22-008322 · doc4.xml · nonDerivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,749 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:29 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 3,458 | $139.22 | $481,422.76 |
DisclosureSEC source: 0001225208-22-008322 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2022. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 21:35 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,000 | $250.00 | $1,250,000.00 |
DisclosureSEC source: 0001225208-22-005738 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,749 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:18 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003755 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,749 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2019-2021 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:49 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,383 | $0.00 Strike: $227.02 | $0.00 |
DisclosureSEC source: 0001225208-22-003490 · doc4.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,383 Underlying: Common Stock, $.01 Par Value · 9,383 shares Expires 2032-02-23 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:49 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003490 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,121 F1 · shares: These restricted stock units vest in three equal annual installments beginning March 1, 2023. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 3,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004356 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,028 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,184 | $0.00 Strike: $213.80 | $0.00 |
DisclosureSEC source: 0001225208-21-003979 · doc4.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,184 Underlying: Common Stock, $.01 Par Value · 12,184 shares Expires 2031-02-24 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003979 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,037 F1 · shares: These restricted stock units vest in three equal annual installments beginning March 1, 2022. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 23:38 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,000 | $230.04 | $460,081.00 |
DisclosureSEC source: 0001225208-21-001111 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,482 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 21, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $230.00 to $230.14 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:29 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 6,000 | $220.00 | $1,320,000.00 |
DisclosureSEC source: 0001225208-20-013483 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,482 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 21, 2020. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 4,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003955 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,482 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,007 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0001225208-20-003816 · doc4.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,007 Underlying: Common Stock, $.01 Par Value · 9,007 shares Expires 2030-02-26 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003816 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,098 F1 · shares: These restricted stock units vest in three equal annual installments beginning February 26, 2021. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:51 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,500 | $198.43 | $1,091,366.65 |
DisclosureSEC source: 0001225208-19-014749 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,637 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $198.43 to $198.445 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:24 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004751 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,137 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,898 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004246 · doc4.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,898 Underlying: Common Stock, $.01 Par Value · 8,898 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004246 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,915 F1 · shares: These restricted stock units vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:46 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 12,271 | Not disclosed Strike: $197.35 | Not disclosed |
DisclosureSEC source: 0001567619-18-008661 · doc1.xml · derivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 12,271 shares Expires 2028-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:46 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 12,402 | Not disclosed Strike: $149.14 | Not disclosed |
DisclosureSEC source: 0001567619-18-008661 · doc1.xml · derivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 12,402 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:46 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,562 | Not disclosed Strike: $139.22 | Not disclosed |
DisclosureSEC source: 0001567619-18-008661 · doc1.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 4,562 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:46 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerCommon Stock, $.25 Par Value | 25,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008661 · doc1.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:13 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,271 | Not disclosed Strike: $197.35 | Not disclosed |
DisclosureSEC source: 0001567619-18-008698 · doc1.xml · derivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,271 Underlying: Common Stock, $0.01 Par Value · 12,271 shares Expires 2028-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:13 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,402 | Not disclosed Strike: $149.14 | Not disclosed |
DisclosureSEC source: 0001567619-18-008698 · doc1.xml · derivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,402 Underlying: Common Stock, $0.01 Par Value · 12,402 shares Expires 2027-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:13 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,562 | Not disclosed Strike: $139.22 | Not disclosed |
DisclosureSEC source: 0001567619-18-008698 · doc1.xml · derivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,562 Underlying: Common Stock, $0.01 Par Value · 4,562 shares Expires 2026-03-01 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:13 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 25,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008698 · doc1.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,339 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 18:13 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,562 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-18-015237 · doc4.xml · derivative · entry 5 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,562 Underlying: Common Stock, $.25 Par Value · 4,562 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in three equal annual installments. The first installment became exercisable on March 1, 2017, the second installment became exercisable on March 1, 2018, and the last installment becomes exercisable on March 1, 2019. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 18:13 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,268 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-18-015237 · doc4.xml · derivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,268 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 18:13 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 21,189 | $212.99 | $4,513,028.16 |
DisclosureSEC source: 0001225208-18-015237 · doc4.xml · nonDerivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,339 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $212.9258 to $213.06 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.